Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors
Abstract Introduction To evaluate effectiveness of human urinary kallindinogenase (HUK) in patients with acute ischemic stroke (AIS) according to Chinese ischemic stroke subclassification (CISS) and analyzed risk factors of clinical efficacy. Methods In this retrospective study, 134 patients receive...
Main Authors: | Si‐Qia Chen, Dong‐Yang Mao, Dun‐Can Wei, Wen‐Zhen He |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.1461 |
Similar Items
-
Chinese Ischemic Stroke Subclassification (CISS)
by: Shan eGAO, et al.
Published: (2011-02-01) -
Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke
by: Yun Qian, et al.
Published: (2019-12-01) -
Human urinary kallidinogenase decreases the incidence of post-stroke cognitive impairment in acute ischemic stroke patients
by: Xu Yan, et al.
Published: (2022-04-01) -
Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis
by: Di‐Xiao Yang, et al.
Published: (2021-12-01) -
Treatment of Human Urinary Kallidinogenase Combined with Maixuekang Capsule Promotes Good Functional Outcome in Ischemic Stroke
by: Juexian Song, et al.
Published: (2018-02-01)